These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29054984)

  • 1. Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol.
    Pearson HE; Iida M; Orbuch RA; McDaniel NK; Nickel KP; Kimple RJ; Arbiser JL; Wheeler DL
    Mol Cancer Ther; 2018 Jan; 17(1):204-214. PubMed ID: 29054984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
    Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
    Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Honokiol enhances the sensitivity of cetuximab in KRAS
    Zhu Q; Zhang R; Gu X; Zhao Z; Gao Q; Chen M; Wu Q; Xie T; Sui X
    Theranostics; 2024; 14(14):5443-5460. PubMed ID: 39310106
    [No Abstract]   [Full Text] [Related]  

  • 4. Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs.
    Prasad R; Katiyar SK
    Adv Exp Med Biol; 2016; 928():245-265. PubMed ID: 27671820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking.
    Saeed M; Kuete V; Kadioglu O; Börtzler J; Khalid H; Greten HJ; Efferth T
    Phytomedicine; 2014 Oct; 21(12):1525-33. PubMed ID: 25442261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and synthesis of novel magnolol derivatives with potent anticancer activity in non-small cell lung cancer.
    Tang H; Zhang Y; Li D; Fu S; Tang M; Wan L; Chen K; Liu Z; Xue L; Peng A; Ye H; Chen L
    Eur J Med Chem; 2018 Aug; 156():190-205. PubMed ID: 30006164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Honokiol, a multifunctional tumor cell death inducer.
    Tian W; Xu D; Deng YC
    Pharmazie; 2012 Oct; 67(10):811-6. PubMed ID: 23136712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.
    Singh T; Gupta NA; Xu S; Prasad R; Velu SE; Katiyar SK
    Oncotarget; 2015 Aug; 6(25):21268-82. PubMed ID: 26020804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo.
    Bonner MY; Karlsson I; Rodolfo M; Arnold RS; Vergani E; Arbiser JL
    Oncotarget; 2016 Mar; 7(11):12857-68. PubMed ID: 26871475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities.
    Kumar A; Kumar Singh U; Chaudhary A
    Future Med Chem; 2013 May; 5(7):809-29. PubMed ID: 23651094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets.
    Banik K; Ranaware AM; Deshpande V; Nalawade SP; Padmavathi G; Bordoloi D; Sailo BL; Shanmugam MK; Fan L; Arfuso F; Sethi G; Kunnumakkara AB
    Pharmacol Res; 2019 Jun; 144():192-209. PubMed ID: 31002949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy.
    Huang KJ; Kuo CH; Chen SH; Lin CY; Lee YR
    J Cell Mol Med; 2018 Mar; 22(3):1894-1908. PubMed ID: 29363886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.
    Song JM; Anandharaj A; Upadhyaya P; Kirtane AR; Kim JH; Hong KH; Panyam J; Kassie F
    Oncotarget; 2016 Sep; 7(36):57752-57769. PubMed ID: 27458163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells.
    Lee B; Kim CH; Moon SK
    FEBS Lett; 2006 Oct; 580(22):5177-84. PubMed ID: 16962592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
    Shigemura K; Arbiser JL; Sun SY; Zayzafoon M; Johnstone PA; Fujisawa M; Gotoh A; Weksler B; Zhau HE; Chung LW
    Cancer; 2007 Apr; 109(7):1279-89. PubMed ID: 17326044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells.
    Kaushik G; Ramalingam S; Subramaniam D; Rangarajan P; Protti P; Rammamoorthy P; Anant S; Mammen JM
    Am J Surg; 2012 Dec; 204(6):868-73. PubMed ID: 23231930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Honokiol: a novel natural agent for cancer prevention and therapy.
    Arora S; Singh S; Piazza GA; Contreras CM; Panyam J; Singh AP
    Curr Mol Med; 2012 Dec; 12(10):1244-52. PubMed ID: 22834827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.